Asceneuron : New member appointed to the Board of Directors

Asceneuron appoints experienced CNS clinician Dr Eric Yuen to the Board of Directors

Asceneuron, an emerging leader in the development of orally bioavailable modulators of tau for the treatment of neurodegenerative diseases, announced the appointment of Dr Eric Yuen to its Board of Directors on 20 May 2019.

Dr Eric Yuen, has over 25 years of clinical development experience in central nervous system (CNS) pathologies and has led multiple Phase I-IV development programs for biologics and small molecules obtaining numerous regulatory approvals. He is currently Chief Medical Officer at Talee Bio Inc which he co-founded in addition to RiboNova Inc.

Asceneuron’s lead program ASN120290 is a small molecule inhibitor of the enzyme O-GlcNAcase. Based on its unique mechanism of action, ASN120290 has the potential to become a first in class treatment for progressive supranuclear palsy (PSP) and other tau-related dementias.

Late last year the company appointed CNS specialist Dr Thomas C. Wessel as Chief Medical Officer in its US based team. Asceneuron recently completed a clinical trial with ASN120290 to quantify target engagement in the human brain using positron emission tomography (PET) the results of which will guide dose selection for a trial in PSP planned for later this year.

Read the full press release
Upload the full press release in PDF